New achievements and pharmacotherapeutic approaches to impotence in the elderly

Aging Clinical and Experimental Research

Volumn 15, Issue 3, 2003, Pages 222-233

  Frajese, Gaetano ^a   Pozzi, Flavio ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Aging; Elderly men; Erectile dysfunction; Neuroendocrinology; Pharmacotherapy of male impotence; Sexuality

Indexed keywords

ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANDROGEN; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; APOMORPHINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HORMONE; LUTEINIZING HORMONE; NEUROLEPTIC AGENT; NEW DRUG; NITRATE; PAPAVERINE; PHENTOLAMINE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PLACEBO; POTASSIUM CHANNEL STIMULATING AGENT; PRASTERONE; PROSTAGLANDIN E1; SILDENAFIL; TADALAFIL; TESTOSTERONE; VARDENAFIL; VASOACTIVE AGENT;

AGED; AGING; AREA UNDER THE CURVE; AROUSAL; BACKACHE; BODY MASS; BONE DENSITY; BONE MINERAL; CONJUNCTIVAL HYPEREMIA; DEPRESSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DYSPEPSIA; ENVIRONMENTAL FACTOR; ERECTILE DYSFUNCTION; FATIGUE; FEEDBACK SYSTEM; FLUSHING; FOOD DRUG INTERACTION; HAIR; HEADACHE; HUMAN; IMAGINATION; IMPOTENCE; INTELLECT; MALE; MYALGIA; NEUROENDOCRINOLOGY; NOSE CONGESTION; PAIN; PATHOPHYSIOLOGY; PENIS ERECTION; QUALITY OF LIFE; REVIEW; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SEXUALITY; SKIN MANIFESTATION; SOCIAL ASPECT; TACHYCARDIA; VISUAL STIMULATION; WEIGHT REDUCTION;

EID: 0141990602     PISSN: 15940667     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03324503     Document Type: Review

References (117)

1. AACE Medical guidelines for clinical practice for the evaluation and treatment of male sexual dysfunction: a couple's problem - 2003 Update. Endocr Pract 2003; 9: 77-94.
2. Lue TF. Erectile dysfunction. N Engl J Med 2000; 342: 1802-13.
3. Lizza EF, Rosen RC. Definition and classification of erectile dysfunction: report of the Nomenclature Committee of the International Society of Impotence Research. Int J Impot Res 1999; 11: 141-3.
4. Sachs BD. Contextual approaches to the physiology and classification of erectile function, erectile dysfunction, and sexual arousal. Neurosci Biobehav Rev 2000; 24: 541-60.
5. Alexander EA, Allison AL. Sexuality in older adults. In Reichel W, Ed. Care of the elderly: Clinical aspects of aging, 4th ed. Baltimore: Williams & Wilkins, 1995: 540-6.
6. Mulligan T, Iranmanesh A, Johnson ML, Straume M, Veldhuis JD. Aging alters feedforward and feedback linkages between LH and testosterone in healthy men. Am J Physiol 1997; 42: R1407-13.
7. Kaplan HS. The evaluation of sexual disorders: psychological and medical aspects. New York: Brunner/Mazel, 1983.
8. Goldstein I. Male sexual circuitry. Working Group for the Study of Central Mechanisms of Erectile Dysfunction. Sci Am 2000; 283: 70-5.
9. Blanker MH, Bosch JL, Groeneveld FP, et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001; 57: 763-8.
10. Intili H. Impotence and perceived partner support. Urol Nurs 1998; 18: 279-87.
11. Ware JC. Impotence and aging. Clin Geriatr Med 1989; 5: 301-14.
12. Frajese G, Magnani A, Mencacci-Amalfitano M, et al. Hormonal behavior, stress and male sexual performance. In Pancheri P, Zichella L, Eds. Biorhythms and stress in the physiopathology of reproduction. New York: Hemisphere Publ. Corp, 1988: 445-61.
13. Derby CA, Mohr BA, Goldstein I, Feldman HA, Johannes CB, McKinlay JB. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology 2000; 56: 302-6.
14. Melman A, Gingell JC. The epidemiology and pathophysiology of erectile dysfunction. J Urol 1999; 161: 5-11.
15. McVary KT, Carrier S, Wessells H. The Subcommittee on Smoking and Erectile Dysfunction Socioeconomic Committee, Sexual Medicine Society of North America. Smoking and erectile dysfunction: evidence based analysis. J Urol 2001; 166: 1624-32.
16. Kinsey AC, Pomeroy WB, Martin CE. Sexual behavior in the human male. Philadelphia: WB Saunders & Co, 1948.
17. Meuleman EJ. Prevalence of erectile dysfunction: need for treatment? Int J Impot Res 2002; 14 (Suppl 1): S22-8.
18. Feldman HA, Goldstein I, Hatzichristou D, Krane RJ, Mc Kinlay JB. Impotence and its medical and psychological correlates: results of the Massachussets Male Aging Study. J Urol 1994; 151: 54-61.
19. Feldman AH, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachussetts Male Aging Study. Prev Med 2000; 30: 328-38.
20. NIH Consensus Conference. Impotence: NIH consensus development panel on impotence. JAMA 1993; 270: 83-90.
21. Braun M, Wassmer G, Klotz T, Reifenrath B, Mathers M, Engelmann U. Epidemiology of erectile dysfunction: results of the 'Cologne Male Survey'. Int J Impot Res 2000; 12: 305-11.
22. Chew KK, Earle CM, Stuckey BGA, Jamrozik K, Keogh EJ. Erectile dysfunction in general medicine practice: prevalence and clinical correlates. Int J Impot Res 2000; 12: 41-5.
23. McKinlay JB. The worldwide prevalence and epidemiology of erectile dysfunction. Int J Impot Res 2000; 12 (Suppl 4): S6-11.
24. Chun J, Carson CC III. Physician-patient dialogue and clinical evaluation of erectile dysfunction. Urol Clin North Am 2001; 28: 249-58.
25. Goldstein I. Screening for erectile dysfunction: rationale. Int J Impot Res 2000; 12 (Suppl 4): S147-51.
26. Sullivan ME, Thompson CS, Dashwood MR, et al. Nitric oxide and penile erection: is erectile dysfunction another manifestation of vascular disease? Cardiovasc Res 1999; 15: 658-65.
27. Montorsi F, Salonia A, Deho F, Briganti A, Rigatti P. The ageing male and erectile dysfunction. World J Urol 2002; 20: 28-35.
28. Kaiser FE, Korenman SG. Impotence in diabetic men. Am J Med 1988; 85: 147-52.
29. Zemel P. Sexual dysfunction in the diabetic patient with hypertension. Am J Cardiol 1988; 61: 27H-33.
30. Dey J, Shepherd MD. Evaluation and treatment of erectile dysfunction in men with diabetes mellitus. Mayo Clin Proc 2002; 77: 276-82.
31. Dinulovic D, Radonjic G. Diabetes mellitus/male infertility. Arch Androl 1990; 25: 277-93.
32. Khan MA, Thompson CS, Sullivan ME, Jeremy JY, Mikhailidis DP, Morgan RJ. The role of prostaglandins in the aetiology and treatment of erectile dysfunction. Prostaglandins Leukot Essent Fatty Acids 1999; 60: 169-74.
33. Moreland RB. Pathophysiology of erectile dysfunction: the contributions of trabecular structure to function and the role of functional antagonism. Int J Impot Res 2000; 12 (Suppl 4): S39-46.
34. Archer SL. Potassium channels and erectile dysfunction. Vascul Pharmacol 2002; 38: 61-71.
35. Melman A, Christ GJ. Integrative erectile biology. The effects of age and disease on gap junctions and ion channels and their potential value to the treatment of erectile dysfunction. Urol Clin North Am 2001; 28: 217-31.
36. Schenk G, Melman A, Christ G. Gene therapy: future therapy for erectile dysfunction. Curr Urol Rep 2001; 2: 480-7.
37. Pincus SM, Veldhuis JD, Mulligan T, Iranmanesh A, Evans WS. Effects of age on the irregularity of LH and FSH serum concentrations in women and men. Am J Physiol 1997; 273: E989-95.
38. Plymate SR, Tenover JS, Bremner WJ. Circadian variation in testosterone, sex hormone binding globulin, and calculated nonsex hormone binding globulin bound testosterone in healthy young and elderly men. J Androl 1989; 10: 366-71.
39. Pincus SM, Mulligan T, Iranmesh A, Georghiu S, Godshalk M, Veldhuis JD. Older males secrete luteinizing hormone and testosterone more irregularly, and jointly more asynchronously, than younger males: dual novel facets. Proc Natl Acad Sci USA 1996; 93: 14100-5.
40. Veldhuis JD. Recent insights into neuroendocrine mechanisms of aging of the human male hypothalamic-pituitary-gonadal axis. J Androl 1999; 20: 1-17.
41. Veldhuis JD. Male hypothalamic-pituitary-gonadal axis. In Yen SSC, Jaffe RB, Barbieri RL, Eds. Reproductive Endocrinology. Philadelphia: WB Saunders Co, 1998.
42. Tsitouras PD, Bulat T. The aging male reproductive system. Endo Met Clin North Am 1995; 24: 297-315.
43. Gray A, Feldman HA, Mc Kinlay JB, Longcope G. Age, disease, changing sex hormone levels in middle aged men: results of the Massachussets Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016-25.
44. Bunch TJ, Abraham D, Wang S, Meikle AW. Pituitary radiographic abnormalities and clinical correlates of hypogonadism in elderly males presenting with erectile dysfunction. Aging Male 2002; 5: 38-46.
45. Veldhuis JD, Urban RJ, Lizarralde G, Johnson ML, Iranmanesh A. Attenuation of luteinizing hormone secretory burst amplitude is a proximate basis for the hypoandrogenism of healthy aging in men. J Clin Endocrinol Metab 1992; 75: 52-8.
46. Gray A, Berlin JA, McKinlay JB, Longcope C. An examination of research design effects on the association of testosterone and male aging: the results of a meta-analysis. J Clin Epidemiol 1991; 44: 671-84.
47. Wespes E, Schulman CC. Male andropause: myth, reality, and treatment. Int J Impot Res 2002; 14 (Suppl 1): S93-8.
48. Shalender Bhasin CJ, Bagatell WJ, Bremner SR, et al. Issues in testosterone replacement in older men. J Clin Endocrinol Metab 1998; 83: 3435-48.
49. Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am J Psychiatry 1998; 155: 1310-8.
50. Morgentaler A. Male impotence. Lancet 1999; 354: 1713-8.
51. Weidner W, Altwein J, Hauck E, Beutel M, Bralher E. Sexuality in the elderly. Urol Int 2001; 66: 181-4.
52. Wagner G, and the Lygon Arms Group. A shared care approach to the management of erectile dysfunction in the community. Int J Impot Res 2002; 14: 189-94.
53. Heaton J. New classification system for erectile dysfunction therapies. J Androl 1998; 19: 399-404.
54. Stief CG. Is there a common pathophysiology of erectile dysfunction and how does this relate to new pharmacotherapies? Int J Impot Res 2002; 14 (Suppl 1): S11-6.
55. Pomerantz SM. Monoamine influences on male sexual behavior of non-human primates. In Bancroft J, Ed. The pharmacology of sexual function and dysfunction. Amsterdam: Elsevier, 1995: 201-11.
56. Hull EM. Dopaminergic influences on male rat sexual behavior. In Micevjc PE, Hammer R, Eds. Neurobiological effects of sex steroid hormones. Cambridge: Cambridge University Press, 1995: 234-53.
57. Zarrindast MR, Shokravi S, Samini M. Opposite influences of dopaminergic receptor subtypes on penile erection. Gen Pharmacol 1992; 23: 671-5.
58. Bagdy G, Kalogeras KT, Szemeredi K. Effect of 5-HT1c and 5-HT2c receptor stimulation on excessive grooming, penile erection and plasma oxytocin concentrations. Eur J Pharmacol 1992; 229: 9-14.
59. Argiolas A, Melis MR, Vargiu L, Gessa GL. D(CH2)5Tyr(Me)-[Orn8]vasotocin, a potent oxytocin antagonist, antagonizes penile erection and yawning induced by oxytocin and apomorphine, but not by ACTH-(1-24). Eur J Pharmacol 1987; 134: 221-4.
60. Wessels H, Hansen JG, Fucciarelli K, et al. Melanotropic peptide for the treatment of psychogenic erectile dysfunction: double blind placebo controlled crossover dosing study. J Urol 1998; 160: 389-93.
61. Heaton JP, Adams MA, Morales A. A therapeutic taxonomy of treatments for erectile dysfunction: an evolutionary imperative. Int J Impot Res 1997; 9: 115-21.
62. Melis MR, Succu S, Argiolas A. Dopamine agonists increase nitric oxide production in the paraventricular nucleus of the hypothalamus: correlation with penile erection and yawning. Eur J Neurosci 1996; 8: 2056-63.
63. Heaton JPW. Central neuropharmacological agents and mechanisms in erectile dysfunction: the role of dopamine. Neurosci Biobehav Rev 2000; 24: 561-9.
64. McKenna KE. Some proposals regarding the organization of the central nervous system control of penile erection. Neurosci Behav Rev 2000; 24: 535-40.
65. Giuliano F, Rampin O. Central noradrenergic control of penile erection. Int J Impot Res 2000; 12 (Suppl 1): S13-9.
66. Argiolas A, Hedlund H. The pharmacology and clinical pharmacokinetics of apomorphine SL. BJU Int 2001; 88 (Suppl 3): 30-5.
67. Heaton JPW, Morales A, Adams MA, Johnston B, el-Rashidy R. Recovery of erectile function by the oral administration of apomorphine. Urology 1995; 45: 200-6.
68. Mirone VG, Stief CG. Efficacy of apomorphine SL in erectile dysfunction. BJU Int 2001; 88 (Suppl 3): 25-9.
69. Heaton JPW. Key issues from the clinical trials of apomorphine SL. World J Urol 2001; 19: 25-31.
70. Dula E, Bukofzer S, Perdok R, George M, and the Apomorphine SL Study Group. Eur Urol 2001; 39: 558-64.
71. Pommerville P. Emerging therapies for the management of erectile dysfunction. J Sex Reprod Med 2002; 2: 80-6.
72. Heaton JPW, Dean J, Sleep DJ. Sequential administration enhances the effect of apomorphine SL in men with erectile dysfunction. Int J Impot Res 2002; 14: 61-4.
73. Brown-Sequard CE. Des effects produits chez l'homme par des injections souscutanées d'un liquid retire des testicules frais de cobaye et de chien. CR Seanc Soc Biol 1889; 1: 420-30.
74. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
75. Jain P, Rademaker AW, McVary KT. Testosterone supplementation for erectile dysfunction: results of a meta-analysis. J Urol 2000; 164: 371-5.
76. Morley JE, Perry HM, Kaiser FE, et al. Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study. J Am Geriatr Soc 1993; 41: 149-52.
77. Tserotas K, Merino G. Andropause and the aging male. Arch Androl 1998; 40: 87-93.
78. Young J, Couzinet B, Nahoul K, et al. Panhypopituitarism as a model to study the metabolism of dehydroepiandrosterone (DHEA) in humans. J Clin Endocrinol Metab 1997; 82: 2578-85.
79. Ballard SA, Gingell CJ, Tang K, Turner LA, Price ME, Naylor AM. Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes. J Urol 1998; 159: 2164-71.
80. Turnbull JM, Weinberg PC. Psychological factors involved in impotence. A review of the literature. J Androl 1983; 4: 59-66.
81. Anastasiadis AG, Ghafar MA, Burchardt M, Shabsigh R. Economic aspects of medical erectile dysfunction therapies. Expert Opin Pharmacother 2002; 3: 257-63.
82. Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. Circulation 1999; 99: 168-77.
83. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. N Engl J Med 1998; 338: 1397-414.
84. Wagner G, Montorsi F, Auerbach S, Collins M. Sildenafil citrate (Viagra) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol 2001; 56: M113-9.
85. Nurnberg HG, Hensley PL, Galenberg AJ, Fava M, Lauriello J, Paine S. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA 2003; 289: 56-64.
86. Lewis R, Bennett CJ, Borkon WD, et al. Patient and partner satisfaction with Viagra (sildenafil citrate) treatment as determined by the Erectile Dysfunction Inventory of Treatment Satisfaction Questionnaire. Urology 2001; 57: 960-5.
87. Jarow JP, Burnett AL, Geringer AM. Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722-5.
88. Virag R. Indications and early results of sildenafil (Viagra) in erectile dysfunction. Urology 1999; 54: 1073-7.
89. Fagelman E, Fagelman A, Shabsigh R. Efficacy, safety, and use of sildenafil in urologic practice. Urology 2001; 57: 1141-4.
90. Saenz De Tejada I, Angulo J, Cuevas P, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE 5 inhibitor vardenafil. Int J Impot Res 2001; 31: 282-90.
91. Klotz T, Sachse R, Liedl T, et al. Vardenafil increases penile rigidity and tumescence in erectile dysfunction patients: a RigiScan and pharmacokinetic study. World J Urol 2001; 19: 32-9.
92. Hellstrom W, Gittelman M, Shapiro J, et al. Vardenafil improved erectile function in men with a broad range of erectile dysfunction etiologies and severities. A phase III trial. Int. J. Impot. Res. 2001; 13 (Suppl 5): S65.
93. Porst H, Rosen R, Padma-Nathan H, et al, and the Vardenafil Study Group. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Int J Impot Res 2001; 13: 192-9.
94. Stark S, Sachse R, Liedl T, et al. Vardenafil increases penile rigidity and tumescence in men with erectile dysfunction after a single oral dose. Eur Urol 2001; 40: 181-90.
95. Brock G, Padma-Nathan H, Seger M. Efficacy and tolerability of vardenafil in men with erectile dysfunction following radical prostatectomy. Eur Urol 2002; 1 (Suppl 1): 152.
96. Goldstein I, Young J, Fisher J. Vardenafil: a new selective PDE 5 inhibitor, improves erectile function in patients with diabetes mellitus. Diabetes 2001; 50 (Suppl 2): A114.
97. Mazzu A, Nicholls A, Zinny M. Vardenafil, a new selective PDE-5 inhibitor, interacts minimally with nitroglycerin in healthy middle-aged male subjects. Int J Impot Res 2001; 13 (Suppl 5): S64.
98. Patterson B, Bedding A, Jewell H, Payne C, Mitchell M. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). Eli Lilly and Company, Erl Wood, UK, 2002.
99. Padma-Nathan H, Rosen RC, Shabsigh R, Saikali K, Watkins V, Pullman WE. Cialis[TM] (IC351) provides prompt response and extended period of responsiveness for the treatment of men with erectile dysfunction (ED). 96th Annual Meeting of the American Urological Association. Anaheim, California, June 2-7, 2001 (Abstract).
100. Porst H, Rosen RC, Padma-Nathan H, Varanese L, Anglin G, Giuliano F. Tadalafil allows men with erectile dysfunction to have successful intercourse up to 36 hours postdose. J Urol 2002; 167 (Suppl): 177 (Abstract).
101. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14 (Suppl. 1): S57-64.
102. Padma-Nathan H, McMurray JG, Pullman WE, et al, for the IC351 On-Demand Dosing Study Group. On-demand IC351 (Cialis[TM]) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 2001; 13: 2-9.
103. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A. The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822-30.
104. Brock GB, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002; 168: 1332-6.
105. Brock G, Iglesias J, Toulouse K, et al. Efficacy and safety of IC351 treatment for ED. Eur Urol 2001; 39 (Suppl 5): 106.
106. Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J 2002; 4 (Suppl H): H32-47.
107. Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991; 146: 1564-5.
108. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am 1995; 22: 833-45.
109. Brock GB. Issues in the assessment and treatment of erectile dysfunction: individualizing and optimizing therapy for the "silent majority". Rete Biomedical Communications Corp., 2002. Available at: http://www.Medscape.com. Accessed: April 2003.
110. Brock GB, Tu LM, Linet OI. Return of spontaneous erection during long-term intracavernosal alprostadil (Caverject) treatment. Urology 2001; 57: 536-41.
111. Richter S, Vardi Y, Ringel A, Shalev M, Nissenkorn I. Intracavernous injections: still the gold standard for treatment of erectile dysfunction in elderly men. Int J Impot Res 2001; 13: 172-5.
112. Padma-Nathan H. The efficacy and synergy of polypharmacotherapy in primary and salvage therapy of vasculogenic erectile dysfunction. Int J Implant Res 1990; (Suppl. 2): 257-8.
113. Porst H. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Int J Impot Res 2000; 12 (Suppl 4): S91-100.
114. Linet OI, Ogrinc FG, for the Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med 1996; 334: 873-7.
115. Hatzichristou DG, Apostolidis A, Tzortzis V, Ioannides E, Yannakoyorgos K, Kalinderis A. Sildenafil versus intracavernous injection therapy: efficacy and preference in patients on intracavernous injection for more than 1 year. J Urol 2000; 164: 1197-200.
116. Williams G, Abbou CC, Amar ET, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. Br J Urol 1998; 81: 889-94.
117. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al, for the Medicated Urethral System for Erection (MUSE) Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997; 336: 1-7.